Fintel reports that on January 28, 2026, Cantor Fitzgerald upgraded their outlook for Korro Bio (NasdaqCM:KRRO) from Neutral to Overweight. Analyst Price Forecast Suggests 292.31% Upside As of January ...

HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for ...

Gossamer Bio, Inc. (NASDAQ:GOSS – Free Report) – Investment analysts at Cantor Fitzgerald increased their FY2025 earnings estimates for Gossamer Bio in a report issued on Monday, March 24th. Cantor ...

Fintel reports that on April 29, 2025, Cantor Fitzgerald initiated coverage of Korro Bio (NasdaqCM:KRRO) with a Overweight recommendation. As of April 24, 2025, the average one-year price target for ...

Fintel reports that on October 31, 2025, Cantor Fitzgerald maintained coverage of Cabaletta Bio (NasdaqGS:CABA) with a Overweight recommendation. As of October 30, 2025, the average one-year price ...

Belite Bio (NASDAQ:BLTE – Get Free Report)‘s stock had its “overweight” rating reissued by research analysts at Cantor Fitzgerald in a research note issued to investors on Tuesday,Benzinga reports. A ...

Investing.com - Cantor Fitzgerald has reiterated its Overweight rating on Gossamer Bio Inc. (NASDAQ:GOSS) ahead of upcoming clinical trial results. The stock, currently trading at $2.74 with a market ...